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Abstract
Background: Over the past years laser technology has played a predominant role in prostate surgery, for the
treatment of benign prostate hypertrophy (BPH). Various laser devices have been introduced in clinical practice,
showing good results in terms of complications and urodynamic outcomes efficacy compared with TURP and
Open Prostatectomy.
In this study we describe the efficacy and the safety profile of a novel laser technique, ThuLEP (Thulium Laser
Enucleation of Prostate) that permits a complete anatomical endoscopic enucleation of prostatic adenoma
independently to prostate size.
Methods: 148 patients with a mean age of 68.2 years were enrolled between September 2009 and March 2012
(36 months), and treated for BPH with ThuLEP. Every patient was evaluated at base line according to: Digital Rectal
Examination (DRE), prostate volume, Post-Voided volume (PVR), International Prostate Symptoms Score (I-PSS),
International Index of Erectile Function-5 (IIEF-5), Quality of Life (QoL), PSA values, urine analysis and urine culture,
uroflowmetry. The same evaluation was conducted after a 12 month follow-up. ThuLEP was performed by 2 expert
surgeons.
Results: Our data showed a better post-operative outcome in terms of catheter removal, blood loss, TURP
syndrome, clot retention and residual tissue compared to large series of TURP and OP. Only 1.3% of patients had
bladder wall injury during morcellation. I-PSS, Qmax, Prostate Volume, QoL and PVR showed a highly significant
improvement at 12 month follow-up in comparison to preoperative assessment.
Conclusion: ThuLEP represent an innovative option in patients with BPH. It is a size independent surgical
endoscopic technique and it can be considered the real alternative, at this time, to TURP and even more to Open
Prostatectomy for large prostate, with a complete removal of adenoma and with a low complication rate.
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Background
Over the past decade laser endoscopic surgery has
played a prominent role as an alternative to TURP and
open prostatectomy (OP) for the treatment of benign
prostatic enlargement (BPE) and obstruction (BPO)
[1,2].
Various laser devices have been introduced in clinical
practice during these years, and four groups of laser sys-
tems are currently used: KTP (kalium titanyl phosphate,
KTP:Nd:YAG [SHG]) and LBO (lithium borat, LBO:Nd:
YAG [SHG]); Diode lasers (various); Holmium yttrium-
aluminum-garnet laser (Ho:YAG) and Thulium YAG
(Tm-YAG) the others have been superseded [3,4].
All of these transurethral laser operations need a phy-
siologic sodium solution 0.9% for irrigation, and this
eliminates the risk of hypotonic hypervolaemic TURP
syndrome, that has been reported in large TURP series
[5]. Furthermore, they offer the advantage of decreased
bleeding complications and the possibility to treat
patients with bleeding disorders or anti-coagulative
treatment [6].
The aim of this study is to present and to prove the
efficacy and safety profile of a novel technique , ThuLEP
(Thulium laser enucleation of the prostate), that permits
complete transurethral removal of the transition zone
(enucleation) with the support of the Thulium laser to
combine complete anatomical enucleation with maxi-
mum urodynamic outcome efficacy and with minimal
side effects.
The first Thulium laser was used in clinical practice in
2005 after introduction of the Holmium laser, and since
then has become the most innovative laser technology in
urology [7]. The Thulium laser offers the advantage to
work in continuous wave (cw) mode at a wavelength of
two microns. The Thulium laser offers complete absorp-
tion of laser energy in water. Tm-TAG is suitable for
many transurethral prostate surgical techniques such pros-
tate vaporization (ThuVAP), bladder neck incision [8],
Vaporesection (ThuVARP) [9,10]. It is also indicated for
Vapoenucleation of the prostate [6] that permits a com-
plete removal of the prostatic adenoma using a blunt
mechanical enucleation of the tissue. For some aspects it
is like the “index finger” in open surgery for large prostate
but with the advantages of laser energy to reduce bleeding
and achieve safe hemostasis using the Thulium laser.
Methods
We evaluated 148 patients with a mean age of 68.2 ±
5.03 yrs. (47yrs.-85yrs.) treated for BPH with sympto-
matic LUTS, using the ThuLEP technique between Sep-
tember 2009 and March 2012 (36 months). Inclusion
criteria were: prostate volume 75 cc or greater; urinary
flow rate (Qmax) not greater than 15 ml/sec; an IPSS > 7.
We excluded patients with prostate cancer, neurogenic
bladder dysfunction diagnosed by urodynamic evaluation
and previous lower urinary tract surgery.
We evaluated all patients according to: Digital Rectal
Examination (DRE), prostate volume by TRUS, Post-
Voided Volume (PVR) by abdominal ultrasonography,
International Prostate Symptoms Score (I-PSS) by self-
administered questionnaire, International Index of Erectile
Function-5 (IIEF-5), quality of life (QoL) by self-admini-
strated questionnaire, PSA assay, urine Analysis and urine
Culture. Every patient has performed uroflowmetry, except
those in urinary retention, to determinate Qmax. Patients
with suspicious PSA or with suspicious DRE, underwent a
randomized 12-core needle ultrasonography-guided trans-
rectal prostate biopsy.
ThuLEP was performed by 2 surgeons with experience
with more than 70 procedures and with previous long
experience in endourology for the BPH endoscopic sur-
gery (TURP – HoLEP –ThuVEP). Most of the patients
had spinal anesthesia, except those with failure of regional
anesthesia and failed spinal anesthesia, in these patients
general anesthesia was used.
Here below is described the surgical technique.
Equipment
We used a 26 Fr continuous-flow resectoscope (Karl Storz
GmbH, Tuttlingen, Germany) with a separate working
channel with a 12° lens system visualized the lower urinary
tract. A camera (Karl Storz GmbH, Tuttlingen, Germany)
was connected to the lens for image enlargement and
High Definition (HD) video to document the procedure.
A 2-lm cw-Thulium:YAG laser (RevolixTM 120 W surgi-
cal laser, LISA laser products, Katlenburg, Germany)was
used with a re-usable 550 lm laser fibre (RigiFibTM, LISA
laser products, Katlenburg, Germany) with a blunt spike,
to apply laser energy. The energy was released at 120 W
for incision of the lateral margins of the median lobe and
at the verum montanum and 40 W for coagulation of cap-
sule perforating vessels during blunt enucleation of the
prostatic adenoma. Physiological saline solution at 0,9%
was used for irrigation during the entire procedure.
A mechanical tissue morcellator (Piranha, Richard
Wolf GmbH, Knittlingen, Germany) was used for frag-
mentation in small slices of the prostatic adenoma. The
morcellator worked into the bladder lumen that was dis-
tended during the procedure to avoid bladder wall
injuries.
The morcellator unit consists of a mechanical hand-
piece, control unit, rotating blades with a diameter of
5 mm, suction pump, activated by a foot pedal. The mor-
cellator has to be inserted into the bladder through a
nephroscope that is connected to the outer sheath of the
resectoscope through an adapter (Karl Storz GmbH,
Tuttlingen, Germany). A double inflow allowed the blad-
der distention.
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Surgical technique
The patient is placed in the lithotomic position. Sterile
draping of the patients is prepared while sterile gel is put
in the urethra. The resectoscope is inserted, under vision,
into the bladder. It is recommendable to perform a cysto-
scopy in the way to exclude eventually bladder pathologies
and to have a look at the ureteral orifices. Finally the
resectoscope is pulled back into the prostatic urethra and
a detailed evaluation is made of the bladder neck, the
extent of lobar protrusion, position of verum montanum
and the borders of external urethral sphincter.
The enucleation starts with removal of the prostatic
median lobe. An inverted U-incision at the level of the
verum montanum is placed, to delimitate the distal board
of resection. Bilateral bladder neck incisions close to the
lateral margins of the prostatic median lobe are made at
the 5 and 7 o’clock positions. These incisions are
extended until the distal third of the verum montanum,
board the entire median lobe. Finally a deeper incision
can be made so the surgical capsule can be visible. It is a
white layer with superficial small vessels. At this time, it
is possible to start the blunt retrograde enucleation of the
prostatic median lobe. The enucleation technique is per-
formed with the resectoscope that is used like a retractor,
that is pushed and bluntly shifted towards the 12 o’clock
direction the median lobe. This action has to be con-
ducted under the edge of the median lobe that is softly
separated from the surgical capsule. The surgical capsule
is used as a natural cleavage plane, as has been done with
an index finger in the open prostatectomy. During blunt
disconnection of the adenoma, laser coagulation of per-
forating vessels of the surgical capsule is necessary and
needs to be continued until the bladder neck is gained.
When complete disconnection of the median lobe from
the surgical capsule is reached, the adenoma can be
pushed into the bladder lumen.
The lateral lobes are removed separately, beginning with
the smaller one if the adenoma is asymmetric, we begin
conventionally from the left lobe for symmetric adenoma.
The first incision is made at the distal margin of the ade-
noma at the 12 o’clock position. From the U-inverted inci-
sion, two superficial incisions towards the 4 o’clock (left
lobe) and 8 o’clock (right lobe) positions are carried out.
The apical board of the lateral lobes is then incised
between the incisions at 12 o’clock position and the inci-
sion at 4 o’clock or 8 o’clock. At this time the bluntly
shifted process can be done in the same way we described
for the median lobe, but in this case it is necessary to pull
the lateral left lobe towards the 2 o’clock position and the
lateral right lobe at 10 o’clock into the bladder lumen. The
surgical capsule can be identified by visualizing the white
layer and small perforating vessels. It is necessary to coa-
gulate these small vessels and use a 40 W energy until the
bladder neck is reached. Again, after complete release
from the surgical capsule, the lateral lobe is pushed into
the bladder. The same procedure is then identically
repeated on the other side.
When the entire adenoma has been pushed into the
bladder lumen the resectoscope is replaced by a nephro-
scope adapted for the morcellator. The suction pump
attracts the pieces of the adenoma and the blades frag-
ment them. This procedure is done with continuous
irrigation and a fully distended bladder to avoid any
bladder wall injuries. The procedure ends with a 22 Fr
catheter.
The catheter was removed after 48 hours from the sur-
gery. Patients were discharged home after a successful
voiding trial after the catheter removal. All complications
were recorded and blood loss was estimated by hemoglo-
bin blood evaluation 24 hours after surgery. Enucleated
tissue was histopathologically evaluated in all cases.
Post-surgery follow-up was conducted after 12 months
from surgery and each patient was evaluated for TRUS,
PSA value, Qmax, PVR, IPSS, IIEF-5 and QoL. All
patients were asked about any complication encountered
during the previous 12 months.
Statistical analysis was performed by the program Sta-
tistical Package for Social Sciences for Windows, version
11.5.1 (SPSS Inc., Chicago, IL, USA).
We expressed patient data according to: mean +/- SD
or as median with interquartile range. We calculated
data paired between pre and post-operative using t-test
with p<0,05 considered statistically significant.
Results and discussion
In Table 1 there is the list of baseline and follow-up char-
acteristics of the patients. Thirty-nine patients (26.3%) had
urinary retention before surgery and were not able to void
without catheter. 105 patients (70.9%) had a gland volume
> 90 gr. Table 2 lists perioperative data. The ThuLEP pro-
cedure was successfully completed in all patients. None of
the patients had ureteric orifice injury, TURP syndrome,
clot retention or incomplete morcellation. In 2 patients
(1.3%) a bladder wall injury during morcellation occurs. 4
patients (2.7%) required early recatheterization after sur-
gery and cystoscopy showed residual tissue at the apex of
prostate fossa. 4 patients (2.7%) needed early postoperative
blood transfusion due to persistent hematuria with contin-
uous bladder irrigation and prolonged catheterization. 10
patients (6.7%) had postoperative irritative symptoms with
temporary urge incontinence, by the way none of them
had these symptoms at 12 months follow-up. UTI
occurred in 19 patients (12.8%) everyone of them received
adequate antibiotic therapy. 2 patients developed urethral
stricture during follow-up, they needed surgery with cold
incision of the stricture part.
Histopathological examination of the enucleated tissue
showed an incidental adenocarcinoma of the prostate in
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8 patients (5.4%) and a benign prostate hyperplasia in
140 patients (94.5%). Four patients died during follow-
up, while 14 did not come to the follow-up evaluation,
they were phoned and asked if any complication
occurred during the follow-up. Patients with adenocarci-
noma of the prostate were excluded from the 12 month
follow-up control and from further analysis they were
treated separately according to their oncological situa-
tion. Therefore of the 148 eligible patients, only 122 of
them were available at 12 months follow-up.
I-PSS, Qmax, prostate volume, QoL and PVR showed
a highly significant improvement at 12 months follow-
up in comparison to preoperative assessment.
BPO with all correlate symptoms (LUTS) is one of the
most frequent pathologies in urological daily practice.
Transurethral resection of the prostate (TURP) in all its
various forms is the predominant procedure performed
worldwide for small adenomas. Open simple prostatectomy
is the treatment option for large prostate. However, both
methods are associated with relevant morbidity. A review
of 9,538 patients, compared surgical outcome between
TURP and OP showed an overall complication rate(blood
transfusion, epididymitis, bladder neck contraction, uretral
stricture and postoperative erectile dysfunction) of
15% for TURP and 21% for OP [95% CI 7.0-42.7] [11].
Another large series of 10,654 patients showed that TURP
has an overall morbidity rate of 11.1% and an overall mor-
tality rate of 0.1%. The most frequent complications were
in order: failure to void (5.8%), surgical revision due to
bleeding (5.6%), requiring blood transfusion (2.9%), TUR
syndrome (1.4%) [12].
On the other hand OP showed in a recent series a com-
plication rate of 15%, with a rate of severe bleeding of 12%
with a transfusion rate approximately of 8.2%; this series
showed a catheterization time of 7 days [13]. One series
reports a transfusion rate up to 26.5% for OP [14]. There-
fore new techniques have been proposed during the last
5 years, with the improvement of surgical technology.
Laser-based treatment such as HoLEP showed in rando-
mized controlled trials, a significant decreased in morbidity,
with a good release of obstructive symptoms, and a totally
size-independent method for the treatment of BPO [15,16].
The aim of our study is to evaluate the efficacy of a new
technique (ThuLEP) developed for the first time in 2009
by Imkamp et al. [17]. However no data are yet dealt with
this kind of transurethral approach comparing it to other
laser techniques or compared with “more standard” tech-
niques. Our data show a good safe profile for ThuLEP, the
most common complication rates were in order: UTI
(12.8%), irritating symptoms (6.7%), re-catheterization
Table 1
Preoperative Mean ± SD (Range) Postoperative Mean ± SD (Range)
No. of patients 148 122
Age (years) 68, 2 ± 5,03 (47 – 85)
PSA (ng/ml) 9,53 ± 8,32 (1,5- 40,2) 0,93 ± 0,67 (0,12 – 3,56)
Prostate Volume (ml) 108,08 ± 24,23 (75 – 210) 13,76 ± 9,47 (4 – 43)
IPSS 21,10 ± 7,12 (8 – 35) 3,90 ± 2,42 (0 – 14)
QoL 4,38 ± 1, 32 (1 – 6) 0,94 ± 0,67 (0 – 4)
Qmax (ml/sec) 8, 23 ± 3,65 (1,3 – 15) 28,67 ± 10,67 (15 – 56)
PVR (ml) 146,12 ± 132,32 (40 – 600) 12,89 ± 20,87 (1 – 128)
IIEF-5 score 19,3 ± 8,23 (6- 30) 20,3 ± 8,16 (6 – 30)
p< 0,05
Table 2
Mean ± SD (Range)
No. of patients 148
Operation duration (min) 70,03 ± 25,87 (40 – 150)
Enucleation duration (min) 50,34 ± 28,76 (15 – 110)
Morcellation duration (min) 18,23 ± 13,34 (8 – 60)
Enucleation efficiency (weight/laser duration) (g/min) 2,34 ± 0,87 (0,97 – 5,34)
Morcellation efficiency (weight/morcellation duration) (g/min) 5,23 ± 1,04 (1,32 – 12,34)
Haemoglobin decrease (g/dl) 1,27 ± 0,88 (0,53 – 4,55)
Catheter time (days) 2,04 ± 0,45 (1 – 7)
Hospitalization (days) 2,15 ± 0,39 (2 – 5)
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(2.7%). Our data show a transfusion rate of 2.7% and a re-
catheterization rate of 2.7%. Bladder wall injury was 1.3%.
It should be stressed that this procedure is indepen-
dent from the prostate size. We treated patients from 75
to 210 gr. of prostate, despite TURP and OP. Some
authors have showed an increased risk of complication
and increased risk of morbidity when large volume pros-
tates are treated [18]. ThuLEP was introduced to over-
come these problems with the same or even better
results in term of overall complication rate and overall
survival rate.
We believe that ThuLEP will be, in the future, the alter-
native of TURP and of OP to treat BPO because it offers
the advantages of endoscopic, minimally invasive surgical
intervention, with the advantages of anatomical blunt dis-
section of the adenoma like the index finger in the open
prostatectomy, with a small complication rate. Laser
energy is used only to describe the correct border of dis-
section at the prostate apex, at the bladder neck and at the
prostate lobes. Furthemore Thulium YAG laser offers a
maximum haemostasis for three reasons. The first reason
is that ThuYAG energy is delivered in a continuous-wave
mode, which can provide excellent coagulation [19].
The second reason has been explained by Bach et al.
[20] that showed a better bleeding control using 120-W
Tm:YAG device despite 70-W Tm:YAG device. The
third reason is that in ThuLEP the adenoma is a blunt
dissect with the resectoscope. This allows the surgeon
to see and to coagulate vessels that come out from the
prostate surgical capsule during the dissection, with
maximum control of the haemostasis [6,17].
Furthermore with ThuLEP it is expected that no pro-
static tissue of the adenoma is left behind. This should
imply a better outcome in terms of uroflowmetry, post-
void residual urine, IPSS, and re-treatment. Capsule per-
foration is almost impossible because the surgical
capsule is always visible, and this decreases the possibi-
lity of erectile dysfunction due to damage of the neuro-
vascular bandels due to a pseudocapsule perforation at
the level of the lateral lobes.
Conclusions
ThuLEP represent a safe, effective surgical option in
patients with symptomatic BPH. It can be considered, at
this time, the real alternative to TURP and even more
to OP for large prostate. Our data showed that this
technique is size-independent, with complete removal of
the adenoma, reduction in TRUS volume and PSA value
in this way it can be compared to open prostatectomy.
It is also safe, with a low complication rate and it can
be used in patients under anticoagulant/antiplatelet
therapy.
In expert hands morcellation does not seem to
improve the complication rate.
Further studies are needed for this technique to enter
into daily surgical practice.
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